IOBT News and Press, IO Biotech Inc. From 05/11/23

2023-05-11 17:25:15 ET IO Biotech press release ( NASDAQ: IOBT ): Q1 GAAP EPS of -$0.59 beats by $0.09 . For further details see: IO Biotech GAAP EPS of -$0.59 beats by $0.09

The company expects to enroll 225 patients in its Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma by mid-2023 and to fully enroll the trial by the end of 2023. The Phase 3 trial protocol calls for an interim analysis of overall response rate (ORR) one year after 225 patients have ...

IO Biotech press release ( NASDAQ: IOBT ): Q3 GAAP EPS of -$0.56 in-line. Cash and cash equivalents as of September 30, 2022, were $151.2 million, compared to $211.5 million at December 31, 2021. Cash on hand is expected to support operations through anticipated data r...

- Preclinical data showing the rationale for two new pipeline candidates targeting the immunosuppressive effects of Arginase-1 (ARG1) and Transforming Growth Factor Beta 1 (TGF b 1) were presented in two posters NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:...

Clinical trial site activation, a leading indicator of patient enrollment, has accelerated in the past three months in the company’s global Phase 3 combination trial of IO102-IO103 and KEYTRUDA ® (pembrolizumab) as first-line treatment in advanced melanoma Or...

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has entered into a fourth clinical trial collaboration...

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President an...

IO Biotech ( NASDAQ: IOBT ) announced Thursday the appointment of Amy Sullivan as its new chief financial officer. Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer. Earlier, Sullivan was chief strategy officer for Eur...

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, today announced the appointment of Amy Sullivan as the company’s n...

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced an oral presentation and two poster presentations at the Societ...